1 / 6

New Diagnostic Tools: Relevance to Programs

Explore the relevance of new diagnostic tools in STI programs, including HPV DNA testing, HSV type-specific serologic testing, and Trichomoniasis testing. Discover the benefits of these tests and their role in reducing colposcopy, decreasing transmission of STIs, and preventing neonatal infections. Overcome programmatic barriers and limited resources with evidence-based guidelines and cost-benefit analyses.

martah
Download Presentation

New Diagnostic Tools: Relevance to Programs

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. New Diagnostic Tools: Relevance to Programs Gail Bolan MD Chief, STD Control Branch

  2. HPV DNA Testing • Benefit: to reduce colposcopy • CDC guidelines recommend triage of ASCUS Pap smear • Lack of programmatic capacity to perform quality Pap smears • Prevalence of HPV, ASCUS and HSIL unknown in most program settings

  3. HSV Type Specific Serologic Testing • Benefit: • Decrease HSV Transmission • Impact of serostatus knowledge on condom use and psychological health • Decrease HIV Transmission • Role of asymptomatic HSV in HIV transmission • Prevent Neonatal HSV • Risk of increasing unnecessary C-sections

  4. HSV Type Specific Serology • Test performance characteristics in the real world • QA programs especially in clinic settings • Role of confirmatory testing in low prevalence populations

  5. Trichomoniasis • Benefit: ??? • Role of more expensive testing versus empiric treatment

  6. Programmatic Barriers • No clear clinical guidelines • Limited cost benefit studies using programmatic data • Resources, Resources, Resources

More Related